Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

Stephen O'Brien, MBBS, BSc, PhD MRCPath, MRCP, Leanne Cork, BSc, Valeria Bandeira, MD, Ruth Bescoby, MSc, Letizia Foroni, MD PhD, Lynn Alaily, MSc, RN, NDN, MICR, Wendy Osborne, MBBS, Helen Bell-Gorrod, BSc, Nicholas Latimer, PhD, Jane Apperley, MB ChB MD, Corinne Hedgley, BSc (Hons), Richard Syzdlo, PhD, Jennifer Byrne, MB, ChB, MRCP, MRCPath, MD, Christopher Pocock, MD PhD, Bernard Ramsahoye, MB, ChB, PhD FRCPath, MRCP, Thomas Zwingers, BSc, James Wason, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD

Blood (2018) 132 (Supplement 1): 457.

https://doi.org/10.1182/blood-2018-99-110128

Published: 2018

Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD

Blood (2013) 122 (21): 2735.

https://doi.org/10.1182/blood.V122.21.2735.2735

Published: 2013

Journal Articles

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Pratap Neelakantan, Gareth Gerrard, Claire Lucas, Dragana Milojkovic, Philippa May, Lihui Wang, Christos Paliompeis, Marco Bua, Alistair Reid, Katayoun Rezvani, Stephen O'Brien, Richard Clark, John Goldman, David Marin

Blood (2013) 121 (14): 2739–2742.

https://doi.org/10.1182/blood-2012-11-466037

Published: 2013

Includes: Supplemental data

Journal Articles

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Jacob Grinfeld, Juan M Alonso-Dominguez, Mary Alikian, Mikel Valgañón, PhD, Georgios Nteliopoulos, PhD, Deborah L. White, PhD, FFSc(RCPA), David Marin, Corinne Hedgley, Stephen O'Brien, Richard E. Clark, MD, Richard M Szydlo, Jane Apperley, John M Goldman, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 2555.

https://doi.org/10.1182/blood.V120.21.2555.2555

Published: 2012

Journal Articles

Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.

Jorge E Cortes, MD, Tim H Brümmendorf, H. Jean Khoury, Andreas Hochhaus, MD, Jane Apperley, Stephen O'Brien, Eric Leip, Virginia Kelly, Katherine Ruffner, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2798.

https://doi.org/10.1182/blood.V120.21.2798.2798

Published: 2012

Journal Articles

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

David Marin, Corinne Hedgley, Richard E. Clark, Jane Apperley, Letizia Foroni, Dragana Milojkovic, Christopher Pocock, John M. Goldman, Stephen O'Brien

Blood (2012) 120 (2): 291–294.

https://doi.org/10.1182/blood-2012-01-407486

Published: 2012

Journal Articles

Haemophagocytic Lymphohistiocytosis Following Fludarabine/Cyclophosphamide Chemotherapy for Chronic Lymphocytic Leukaemia

Deepa Ranjani Jayakody Arachchillage, Samuel Moses, Stephen O'Brien, Tobias Menne, Peter Carey, Fiona Keenan, Jonathan Wallis

Blood (2011) 118 (21): 4617.

https://doi.org/10.1182/blood.V118.21.4617.4617

Published: 2011

Journal Articles

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

David Marin, Corinne Hedgley, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Letizia Foroni, MD PhD, Dragana Milojkovic, MD, Christopher Pocock, John M Goldman, Stephen O'Brien

Blood (2011) 118 (21): 785.

https://doi.org/10.1182/blood.V118.21.785.785

Published: 2011

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

Journal Articles

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Xiaoyan Jiang, MD, PhD, Hannah Grant, PhD, Justin Stebbing, MD, PhD, Letizia Foroni, MD, Charles Craddock, BM, MRCP, MRCPah, MD, Mike Griffiths, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, MD, PhD, Jamshid S. Khorashad, MD, PhD, Gareth Gerrard, MD, PhD, Lihui Wang, MD, PhD, Julie Irving, PhD, Meng Wang, PhD, Loraine Karran, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Donna L. Forrest, MD, Karen Page, MA, PhD, Connie J. Eaves, PhD, Adrian Woolfson, PhD

Blood (2010) 116 (21): 3397.

https://doi.org/10.1182/blood.V116.21.3397.3397

Published: 2010

Journal Articles

Dasatinib in accelerated phase

Stephen O'Brien

Blood (2007) 109 (10): 4110.

https://doi.org/10.1182/blood-2007-03-075721

Published: 2007

Journal Articles

Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib

Feng Lin, Mark Drummond, Stephen O'Brien, Francisco Cervantes, John Goldman, Jaspal Kaeda

Blood (2003) 102 (3): 1143.

https://doi.org/10.1182/blood-2002-12-3916

Published: 2003

NARROW

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

Haemophagocytic Lymphohistiocytosis Following Fludarabine/Cyclophosphamide Chemotherapy for Chronic Lymphocytic Leukaemia

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Dasatinib in accelerated phase

Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only